Please ensure Javascript is enabled for purposes of website accessibility
Home > Support > Literature Updates

In vivo immunoengineering of the immune system

Science Immunology

The November 2026 issue features a Review on in vivo immunoengineering. Immune cells are modified directly within the body. Strategies for checkpoint blockade and cellular therapies are discussed in the context of direct in vivo programming of immune responses.

Related products

Catalog No. Product Name Description Target
HS870026 Anti-Human PD-1 Reference Antibody (Pembrolizumab Pembrolizumab (HS870026) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns. CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1